Immune Checkpoint Inhibitor Rechallenge in a Patient With Previous Fulminant Myocarditis
Immune Checkpoint Inhibitor Rechallenge in a Patient With Previous Fulminant Myocarditis
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
A week after initial evaluation, his TTE showed an acutely decreased LVEF to 20% to 25%, with severe global hypokinesia of the left ventricle but no focal wall motion abnormalities. [...]he received 2 doses each of abatacept (CTLA-4 agonist) 500 mg intravenous (IV) and ruxolitinib (Janus kinase inhibitor) 15 mg. In a case series of 35 patients, Mah...
Alternative Titles
Full title
Immune Checkpoint Inhibitor Rechallenge in a Patient With Previous Fulminant Myocarditis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2820337899
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2820337899
Other Identifiers
ISSN
0002-9149,1879-1913
E-ISSN
1879-1913
DOI
10.1016/j.amjcard.2023.04.037
